A strong per­for­mance by AMG510 stokes fresh en­thu­si­asm on the fu­ture of Am­gen's land­mark KRAS G12C pro­gram — but shares slide

Dave Reese (Am­gen)

In the run-up to to­day’s an­nounce­ment from Am­gen on the lat­est up­date to come out of their de­vel­op­ment ef­fort on AMGN510, Am­gen R&D chief Dave Reese was well aware of the in­tense an­tic­i­pa­tion build­ing up.

“I’ve nev­er seen this kind of in­ter­est in a Phase I,” he says, and that’s say­ing some­thing for some­one who’s an on­col­o­gist by back­ground.

Reese’s bot­tom line go­ing in­to the pre­sen­ta­tion Sun­day in Barcelona at the World Con­fer­ence on Lung Can­cer: “We re­main in­cred­i­bly en­thu­si­as­tic.”

For good rea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER